Extracted Trials
Select a trial for this version to view the audit.
NCT02998528
CheckMate 816Forde PM et al. (2022)
Eligibility Criteria
Inclusion Criteria
Inclusion Criteria: * Early stage IB-IIIA, operable non-small cell lung cancer, confirmed in tissue * Lung function capacity capable of tolerating the proposed lung surgery * Eastern Cooperative Oncology Group (ECOG) Performance Status of 0-1 * Available tissue of primary lung tumor
Exclusion Criteria
Exclusion Criteria: * Presence of locally advanced, inoperable or metastatic disease * Participants with active, known or suspected autoimmune disease * Prior treatment with any drug that targets T cell co-stimulations pathways (such as checkpoint inhibitors) Other protocol defined inclusion/exclusion criteria apply
Bibliographic Info
- Trial Acronym:
- CheckMate 816
- First Author:
- Forde PM
- Year:
- 2022
- PMID:
- 35403841
Patient Baseline
- N (Intervention):
- 179
- N (Control):
- 179
- Median Follow-up:
- 30 months
Intervention Details
Experimental Arm
- •
Control Arm
- •